H.R. 5668 · 116th Congress

Making Objective Drug Evidence Revisions for New Labeling Act of 2020

Stage
Passed a chamber
Sponsor
Doris Matsui
Introduced
2020-01-24
Latest action
2020-11-18 · Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Action history

  1. 2020-11-18Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  2. 2020-11-17Motion to reconsider laid on the table Agreed to without objection.
  3. 2020-11-17On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  4. 2020-11-17DEBATE - The House proceeded with forty minutes of debate on H.R. 5668.
  5. 2020-11-17Considered under suspension of the rules.
  6. 2020-11-17Mr. Pallone moved to suspend the rules and pass the bill, as amended.
  7. 2020-11-16Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-573.
  8. 2020-11-16Placed on the Union Calendar, Calendar No. 471.
  9. 2020-07-15Committee Consideration and Mark-up Session Held.
  10. 2020-07-15Ordered to be Reported (Amended) by Voice Vote.
  11. 2020-03-11Ordered to be Reported (Amended) by Voice Vote.
  12. 2020-03-11Subcommittee Consideration and Mark-up Session Held.
  13. 2020-01-25Referred to the Subcommittee on Health.
  14. 2020-01-24Introduced in House
  15. 2020-01-24Referred to the House Committee on Energy and Commerce.